Skip to main content
SpringerLink
Log in

Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To compare the timing and pattern of recurrence in patients with advanced ovarian cancer (AOC) receiving primary debulking surgery (PDS) versus neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS).

Methods

We retrospectively evaluated a consecutive series of 175 stage IIIC–IV epithelial ovarian cancer patients, with diffuse peritoneal carcinomatosis documented at initial surgical exploration. Forty patients received complete PDS, and the remaining 135 were treated with NACT followed by IDS with absent residual tumor after surgery.

Results

No differences were observed in the distribution of clinical pathological characteristics at the time of diagnosis between the two groups. The median follow-up was 31 months (range 9–150 months). We observed 20 (50.0 %) recurrences in the PDS group compared to 103 (76.3 %) in the IDS group (p = 0.001). Duration of primary platinum-free interval (PFI) was shorter in IDS compared to PDS group (13 vs. 21 months, respectively; p = 0.014). A significantly higher percentage of patients in the IDS group experienced platinum-resistant recurrences (35.9 vs. 5.0 %; p = 0.006) and carcinomatosis at the time of relapse (57.3 vs. 20.0 %; p = 0.0021). Finally, in women with platinum-sensitive recurrence, we observed a shorter secondary PFI in the IDS compared to PDS group (p = 0.006).

Conclusions

We documented a better behavior of recurrent disease in AOC patients with diffuse peritoneal carcinomatosis treated with complete PDS compared to women submitted to NACT followed by IDS with no residual tumor after surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006;100:283–7.

    Article  PubMed  Google Scholar 

  2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  3. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559–64.

    Article  PubMed  CAS  Google Scholar 

  4. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.

    Article  PubMed  Google Scholar 

  5. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390–6.

    Article  PubMed  Google Scholar 

  6. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–92.

    Article  PubMed  Google Scholar 

  7. Vergote I, Tropé CG, Amant F, et al. European Organization for Research and Treatment of Cancer–Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2012;363:943–53.

    Article  Google Scholar 

  8. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2012;(8):CD005343.

  9. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–93.

    PubMed  CAS  Google Scholar 

  10. Hoskin P, O”Reilly S, Swenerton K. The “failure free interval” defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer. 1991;1:205–8.

    Article  Google Scholar 

  11. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer. 2006;42:2296–302.

    Article  PubMed  Google Scholar 

  12. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol. 1997;8:963–8.

    Article  PubMed  CAS  Google Scholar 

  13. Skipper HE. Adjuvant chemotherapy. Cancer. 1978;41:936–40.

    Article  PubMed  CAS  Google Scholar 

  14. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–33.

    PubMed  CAS  Google Scholar 

  15. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012;124:10–4.

    Article  PubMed  Google Scholar 

  16. Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120:23–8.

    Article  PubMed  Google Scholar 

  17. Kaplan FL, Meier P. Non parametric estimation from incomplete observations. Am J Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.

    PubMed  CAS  Google Scholar 

  19. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:197–220.

    Google Scholar 

  20. Matsuo K, Eno ML, Im DD, Rosenshein NB. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch Gynecol Obstet. 2010;281:325–8.

    Article  PubMed  CAS  Google Scholar 

  21. Dutta T, Sharma H, Kumar L, et al. Neoadjuvant chemotherapy for epithelial ovarian cancer—role of apoptosis. Cancer Chemother Pharmacol. 2005;56:427–35.

    Article  PubMed  CAS  Google Scholar 

  22. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933–9.

    Article  PubMed  Google Scholar 

  23. Pfisterer J, Harter P, Canzler U, et al. AGO Ovarian Committee; AGO Ovarian Cancer Study Group (AGO-OVAR). The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15(Suppl 3):195–8.

    Article  PubMed  Google Scholar 

  24. Cantù MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 2002;20:1232–7.

    Article  PubMed  Google Scholar 

  25. Lee CK, Simes RJ, Brown C, et al. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer. 2011;105:1144–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy

    M. Petrillo MD, G. Ferrandina MD, G. Vizzielli MD, P. A. Margariti MD, Anchora L. Pedone MD, C. Nero MD, F. Fanfani MD & Giovanni Scambia MD

  2. Department of Obstetrics and Gynecology, University of Perugia, Perugia, Italy

    A. Fagotti MD

Authors
  1. M. Petrillo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Ferrandina MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Fagotti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Vizzielli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. A. Margariti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anchora L. Pedone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Nero MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Fanfani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giovanni Scambia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Scambia MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petrillo, M., Ferrandina, G., Fagotti, A. et al. Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. Ann Surg Oncol 20, 3955–3960 (2013). https://doi.org/10.1245/s10434-013-3091-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-013-3091-6

Keywords

Search

Navigation